Top

Published in:

01-07-2012 | Dementias - Original Article

Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment

Authors: Marcin Kruczyk, Henrik Zetterberg, Oskar Hansson, Sindre Rolstad, Lennart Minthon, Anders Wallin, Kaj Blennow, Jan Komorowski, Mats Gunnar Andersson

Published in: Journal of Neural Transmission | Issue 7/2012

Abstract

The objective of the present study was to evaluate a Monte Carlo feature selection (MCFS) and rough set Rosetta pipeline for generating rule-based models as a tool for comprehensive risk estimates for future Alzheimer’s disease (AD) in individual patients with mild cognitive impairment (MCI). Risk estimates were generated on the basis of age, gender, Mini-Mental State Examination scores, apolipoprotein E (APOE) genotype and the cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phospho-tau₁₈₁ (P-tau) and the 42 amino acid form of amyloid β (Aβ42) in two sets of longitudinally followed MCI patients (n = 217 in total). The predictive model was created in Rosetta, evaluated with the standard tenfold cross-validation approach and tested on an external set. Features were ranked and selected by the MCFS algorithm. Using the combined pipeline of MCFS and Rosetta, it was possible to predict AD among patients with MCI with an area under the receiver operating characteristics curve of 0.92. Risk estimates were produced for the individual patients and showed good correlation with actual diagnosis in cross validation, and on an external dataset from a new study. Analysis of the importance of attributes showed that the biochemical CSF markers contributed the most to the predictions, and that added value was gained by combining several biochemical markers. Despite a correlation with the biochemical markers, the genetic marker APOE ε4 did not contribute to the predictive power of the model.

American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Arlington

Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A (2001) Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12:851–855PubMedCrossRef

Blennow K, Zetterberg H (2006) Pinpointing plaques with PIB. Nat Med 12:753–754PubMedCrossRef

Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403PubMedCrossRef

Borroni B, Anchisi D, Paghera B, Vicini B, Kerrouche N, Garibotto V, Terzi A, Vignolo LA, Di Luca M, Giubbini R, Padovani A, Perani D (2006) Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 27:24–31PubMedCrossRef

Breiman L (2001) Random forests. Mach Learn 45:5–32CrossRef

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30:682–690PubMedCrossRef

Chetelat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B (2005) FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14–25PubMedCrossRef

Draminski M, Rada-Iglesias A, Enroth S, Wadelius C, Koronacki J, Komorowski J (2009) Monte Carlo feature selection for supervised classification. Bioinformatics 25:1165–1172CrossRef

Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367:1262–1270PubMedCrossRef

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry 9:705–710PubMed

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234PubMedCrossRef

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2007) Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging 30:165–173PubMedCrossRef

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 21:1119–1128PubMed

Herukka SK, Hallikainen M, Soininen H, Pirttilä T (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 6:1294–1297CrossRef

Hvidsten TR, Komorowski J (2007) Rough sets in bioinformatics. In: Marek VW, Orlowska E, Slowinski R, Ziarko W (eds) Transactions on rough sets VII. LNCS, vol 4400. Springer, Heidelberg, pp 225–243

John GH, Langley P (1995) Estimating continuous distributions in Bayesian classifiers. In: Proceedings of the eleventh conference on uncertainty in artificial intelligence, San Mateo, pp 338–345

Kierczak MDM, Koronacki J, Komorowski J (2010) Computational analysis of molecular interaction networks underlying change of HIV-1 resistance to selected reverse transcriptase inhibitors. Bioinform Biol Insights 4:137–146PubMed

Le Cessie S, van Houwelingen JC (1992) Ridge estimators in logistic regression. Appl Stat 41:191–201CrossRef

Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schönknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4PubMedCrossRef

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393PubMedCrossRef

Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386–395PubMedCrossRef

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedCrossRef

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ (2005) Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64:1860–1867PubMedCrossRef

Nguyen HS (2006) Approximate Boolean reasoning: foundations and applications in data mining. LNCS 4100:334–506

Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76:1485–1490PubMedCrossRef

Pawlak Z (1982) Rough sets. Int J Parallel Program 11:341–356

Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194PubMedCrossRef

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729–1734PubMedCrossRef

Shaw LM, Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413PubMedCrossRef

Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46:235–240PubMedCrossRef

Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8:619–627PubMedCrossRef

Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci Lett 352:67–69PubMedCrossRef

Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 12:255–260PubMed

Title: Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment
Authors: Marcin Kruczyk
Henrik Zetterberg
Oskar Hansson
Sindre Rolstad
Lennart Minthon
Anders Wallin
Kaj Blennow
Jan Komorowski
Mats Gunnar Andersson
Publication date: 01-07-2012
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 7/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0812-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2012

Biomarkers of neurodegeneration – not only Alzheimer’s disease and not only cerebrospinal fluid: a guest-editor’s introduction

A novel ARC gene polymorphism is associated with reduced risk of Alzheimer’s disease

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Clinical phenotypes and genetic biomarkers of FTLD

Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report

Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer’s disease patients